Bulk Inquiry
AZD1656
Axon 3062
CAS:
919783-22-5
- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C24H26N6O5
- MW: 478.5
Description
AZD1656 is a potent, selective glucokinase (GK) activator that progressed to Phase IIb trials for the treatment of type 2 diabetes.
More Information
| Parent CAS No. | 919783-22-5 |
|---|---|
| Chemical Name | (S)-3-(5-(Azetidine-1-carbonyl)pyrazin-2-yloxy)-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide |
| SMILES | C1(O[C@@H](C)COC)C=C(C(=O)NC2=CN=C(C)C=N2)C=C(OC2C=NC(C(N3CCC3)=O)=CN=2)C=1 |&1:2,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1 |
| InChiKey | FJEJHJINOKKDCW-INIZCTEOSA-N |
| CID | 16039797 |
| Short Description | GK activator |
References
- MJ Waring et al. Property based optimisation of glucokinase activators - discovery of the phase IIb clinical candidate AZD1656. Med. Chem. Commun., 2012, 3, 1077-1081.
- D McKerrecher et al. Design and development of the glucokinase activator AZD1656. ACS Symposium Series (2018), 1307(Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry, Volume 1), 185-220.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1134 | RO 28-0450 |
From $143.00 |
| 1355 | RO 28-1674 |
From $143.00 |
| 1356 | RO 28-1675 |
From $115.50 |
Other Categories
Get a Quote for
Loading...
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.